ConductScience.org, home

Paper6800533

Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist.

Wenting GJ and 4 others. Br Med J (Clin Res Ed), 1982. Cited by 133 papers, by iCite.

Cite this record

ConductScience Library. Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist. Papers, record 6800533. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6800533

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist.
PubMed
Journal
Br Med J (Clin Res Ed)
PubMed
Year
1982
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
133
iCite
Relative citation ratio, by iCite
7.49
iCite
Revised in PubMed
2019-05-01
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wenting GJG J
2Man in 't Veld AJA J
3Woittiez AJA J
4Boomsma FF
5Schalekamp MAM A

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
HypertensionMajor topic
PiperidinesMajor topic
Receptors, SerotoninMajor topic
Adult
Aged
Cardiac Output
Female
Heart Rate
Humans
Ketanserin
Kidney
Male
Middle Aged
Norepinephrine
Vascular Resistance

Source PubMed

Download CSV of topics

References10

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
15411466Abnormal renal haemodynamics and renin suppression in hypertensive patients.Clin Sci1970https://conductscience.org/library/papers/5411466PubMed
21128155A sensitive radioenzymatic assay for norepinephrine in tissues and plasma.Life Sci1975https://conductscience.org/library/papers/1128155PubMed
374464Inactive renin in human plasma.Lancet1976https://conductscience.org/library/papers/74464PubMed
4530254Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol.Mol Pharmacol1979https://conductscience.org/library/papers/530254PubMed
56446522Review of the role of the central serotonergic neuronal system in blood pressure regulation.Hypertension1980https://conductscience.org/library/papers/6446522PubMed
67400317Supersensitivity of atherosclerotic rabbit aorta to ergonovine. Mediation by a serotonergic mechanism.J Clin Invest1980https://conductscience.org/library/papers/7400317PubMed
76261070Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors.Life Sci1981https://conductscience.org/library/papers/6261070PubMed
86112515Acute blood-pressure-lowering effect of ketanserin.Lancet1981https://conductscience.org/library/papers/6112515PubMed
961125315-HT2-receptor blockade in the treatment of heart failure. A preliminary study.Lancet1981https://conductscience.org/library/papers/6112531PubMed
106113280Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors.J Pharmacol Exp Ther1981https://conductscience.org/library/papers/6113280PubMed

Download CSV of references

Cited by32

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 133 citations.

PMIDTitleJournalYearIn PapersSource
41379296Pharmacological effect of quinazoline-2,4(1H,3H)-dione derivatives: a review.Mol Divers2026https://conductscience.org/library/papers/41379296PubMed
22407614Serotonin and blood pressure regulation.Pharmacol Rev2012https://conductscience.org/library/papers/22407614PubMed
204336855-hydroxtryptamine receptors in systemic hypertension: an arterial focus.Cardiovasc Ther2011https://conductscience.org/library/papers/20433685PubMed
6812750Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin.Br Med J (Clin Res Ed)1982https://conductscience.org/library/papers/6812750PubMed
6712863Effect of the 5-hydroxytryptamine type 2 receptor antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympatho-adrenal function in patients with essential hypertension.Br J Clin Pharmacol1984https://conductscience.org/library/papers/6712863PubMed
6712862Acute effects of ketanserin on left ventricular function, metabolism and coronary blood flow.Br J Clin Pharmacol1984https://conductscience.org/library/papers/6712862PubMed
6652362Effects of LM 5008, a selective inhibitor of 5-hydroxytryptamine uptake, on blood pressure and responses to sympathomimetic amines.Br J Pharmacol1983https://conductscience.org/library/papers/6652362PubMed
6628517Ketanserin in essential hypertension: effects during rest and exercise.Eur J Clin Pharmacol1983https://conductscience.org/library/papers/6628517PubMed
6626423The effect of a 5-HT antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympathoadrenal function in normal man.Br J Clin Pharmacol1983https://conductscience.org/library/papers/6626423PubMed
6617728Pharmacokinetics of ketanserin in man.Eur J Clin Pharmacol1983https://conductscience.org/library/papers/6617728PubMed
6615685Ketanserin, a novel 5-hydroxytryptamine antagonist: monotherapy in essential hypertension.Br J Clin Pharmacol1983https://conductscience.org/library/papers/6615685PubMed
6432198Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders.Br Med J (Clin Res Ed)1984https://conductscience.org/library/papers/6432198PubMed
6362688Haemodynamic and humoral responses to chronic ketanserin treatment in essential hypertension.Br Heart J1984https://conductscience.org/library/papers/6362688PubMed
6150724Ketanserin in combination with beta-adrenergic receptor blocking agents in the treatment of essential hypertension.Br J Clin Pharmacol1984https://conductscience.org/library/papers/6150724PubMed
3801767In vivo and in vitro activity of selective 5-hydroxytryptamine2 receptor antagonists.Br J Pharmacol1986https://conductscience.org/library/papers/3801767PubMed
3684842Profound hypotension after the first dose of ketanserin.Postgrad Med J1987https://conductscience.org/library/papers/3684842PubMed
3620282Lack of effect of ketanserin on indices of hepatic enzyme induction.Br J Clin Pharmacol1987https://conductscience.org/library/papers/3620282PubMed
3595699Pharmacokinetics of ketanserin in patients with essential hypertension.Eur J Clin Pharmacol1987https://conductscience.org/library/papers/3595699PubMed
3240727Effect of ketanserin on lipoproteins in patients with essential hypertension.Drugs1988https://conductscience.org/library/papers/3240727PubMed
3240725Effects of ketanserin on systemic and regional haemodynamics in patients with essential hypertension.Drugs1988https://conductscience.org/library/papers/3240725PubMed

See all 32 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
HTR2A3356PubTator's text mininghttps://conductscience.org/library/genes/3356NCBI Gene
REN5972PubTator's text mininghttps://conductscience.org/library/genes/5972NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/6800533

GET https://conductscience.org/api/papers/v1/6800533/cited_by?page=2